Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
About the study
This is an ethics-approved, multi-national, multi-site Phase IV, 1-cohort prospective observational study. The main purpose of this study is to assess the effect of tildrakizumab on the overall wellbeing in patients with moderate-to-severe psoriasis using the 5-item World Health Organization Wellbeing Index (WHO-5) questionnaire.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Patient with diagnosis of moderate-to-severe chronic plaque psoriasis documented in the medical chart.
- Patient who need systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-IL-23p19 selected therapy before including the patient in the study.
- Patient aged 18 years or older at the time of patient recruitment.
- Patient who have provided written informed consent (if required by country regulations).
EXCLUSION CRITERIA
Exclusion Criteria:
- Patients unable to comply with the requirements of the study (fulfilling of the study questionnaires) or who, in the opinion of the study physician, should not participate in the study.
- Patients included in a clinical trial.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Plaque Psoriasis
Age (in years)
18+
Participants needed
782
Est. Completion Date
Dec 31, 2024
Treatment type
Observational [Patient Registry]
Sponsor
Almirall, S.A.
ClinicalTrials.gov identifier
NCT04823247
Study number
M-14745-47
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?